157 related articles for article (PubMed ID: 9707419)
1. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.
Grütz GG; Bucher K; Lavenir I; Larson T; Larson R; Rabbitts TH
EMBO J; 1998 Aug; 17(16):4594-605. PubMed ID: 9707419
[TBL] [Abstract][Full Text] [Related]
2. Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia.
Grutz G; Forster A; Rabbitts TH
Oncogene; 1998 Nov; 17(21):2799-803. PubMed ID: 9840944
[TBL] [Abstract][Full Text] [Related]
3. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins.
Wadman IA; Osada H; Grütz GG; Agulnick AD; Westphal H; Forster A; Rabbitts TH
EMBO J; 1997 Jun; 16(11):3145-57. PubMed ID: 9214632
[TBL] [Abstract][Full Text] [Related]
4. Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.
Ryan DP; Duncan JL; Lee C; Kuchel PW; Matthews JM
Proteins; 2008 Mar; 70(4):1461-74. PubMed ID: 17910069
[TBL] [Abstract][Full Text] [Related]
5. Identification of the key LMO2-binding determinants on Ldb1.
Ryan DP; Sunde M; Kwan AH; Marianayagam NJ; Nancarrow AL; Vanden Hoven RN; Thompson LS; Baca M; Mackay JP; Visvader JE; Matthews JM
J Mol Biol; 2006 May; 359(1):66-75. PubMed ID: 16616188
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice.
Larson RC; Osada H; Larson TA; Lavenir I; Rabbitts TH
Oncogene; 1995 Sep; 11(5):853-62. PubMed ID: 7545805
[TBL] [Abstract][Full Text] [Related]
7. The LMO1 and LDB1 proteins interact in human T cell acute leukaemia with the chromosomal translocation t(11;14)(p15;q11).
Valge-Archer V; Forster A; Rabbitts TH
Oncogene; 1998 Dec; 17(24):3199-202. PubMed ID: 9872335
[TBL] [Abstract][Full Text] [Related]
8. The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development.
Rabbitts TH; Bucher K; Chung G; Grutz G; Warren A; Yamada Y
Cancer Res; 1999 Apr; 59(7 Suppl):1794s-1798s. PubMed ID: 10197599
[TBL] [Abstract][Full Text] [Related]
9. The Lim-only protein LMO2 acts as a positive regulator of erythroid differentiation.
Hansson A; Zetterblad J; van Duren C; Axelson H; Jönsson JI
Biochem Biophys Res Commun; 2007 Dec; 364(3):675-81. PubMed ID: 17964543
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional control of fetal liver hematopoiesis: dominant negative effect of the overexpression of the LIM domain mutants of LMO2.
Terano T; Zhong Y; Toyokuni S; Hiai H; Yamada Y
Exp Hematol; 2005 Jun; 33(6):641-51. PubMed ID: 15911088
[TBL] [Abstract][Full Text] [Related]
11. Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia.
Hoang T
Sci Transl Med; 2010 Mar; 2(21):21ps10. PubMed ID: 20374994
[TBL] [Abstract][Full Text] [Related]
12. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2.
Larson RC; Fisch P; Larson TA; Lavenir I; Langford T; King G; Rabbitts TH
Oncogene; 1994 Dec; 9(12):3675-81. PubMed ID: 7970726
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy: is IL2RG oncogenic in T-cell development?
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Nature; 2006 Sep; 443(7109):E5; discussion E6-7. PubMed ID: 16988660
[TBL] [Abstract][Full Text] [Related]
14. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes.
Fisch P; Boehm T; Lavenir I; Larson T; Arno J; Forster A; Rabbitts TH
Oncogene; 1992 Dec; 7(12):2389-97. PubMed ID: 1461647
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis.
Rabbitts TH; Axelson H; Forster A; Grutz G; Lavenir I; Larson R; Osada H; Valge-Archer V; Wadman I; Warren A
Leukemia; 1997 Apr; 11 Suppl 3():271-2. PubMed ID: 9209362
[TBL] [Abstract][Full Text] [Related]
16. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Oncogene; 2002 Feb; 21(9):1309-15. PubMed ID: 11857074
[TBL] [Abstract][Full Text] [Related]
17. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
18. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression.
Herblot S; Steff AM; Hugo P; Aplan PD; Hoang T
Nat Immunol; 2000 Aug; 1(2):138-44. PubMed ID: 11248806
[TBL] [Abstract][Full Text] [Related]
19. Development of T-cell lymphomas in Emu-IEX-1 mice.
Zhang Y; Finegold MJ; Porteu F; Kanteti P; Wu MX
Oncogene; 2003 Oct; 22(44):6845-51. PubMed ID: 14534530
[TBL] [Abstract][Full Text] [Related]
20. An activation-responsive element in single C motif-1/lymphotactin promoter is a site of constitutive and inducible DNA-protein interactions involving nuclear factor of activated T cell.
Yoshida T; Ishikawa I; Ono Y; Imai T; Suzuki R; Yoshie O
J Immunol; 1999 Sep; 163(6):3295-303. PubMed ID: 10477599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
